文献速递肿瘤 PET/CT核素与放射性配体治疗

99mTc-PHC-102微剂量SPECT/CT显像用于肾细胞癌原发及转移灶的探索性研究

A Microdosing Study with 99mTc-PHC-102 for the SPECT/CT Imaging of Primary and Metastatic Lesions in Renal Cell Carcinoma Patients.
PubMed 文献 · J Nucl Med · 2020-07-17

本研究在5例局限性或转移性透明细胞肾细胞癌患者中开展微剂量研究,静脉注射50 μg CAIX配体、600-800 MBq 99mTc-PHC-102后于30分钟、2小时、6小时行SPECT/CT。结果显示示踪剂耐受良好,无研究药物相关不良事件,原发肿瘤均见摄取且靶本比良好,并在2例患者中检出4处既往未知的肺及淋巴结转移。

要点

  • 99mTc-PHC-102在5例ccRCC患者中耐受良好,未记录研究药物相关不良事件。
  • 5例患者原发肿瘤均见示踪剂定位,靶本比良好。
  • SPECT/CT在2例患者中识别出4处既往未知的肺和淋巴结转移。

核心结论

  • 99mTc-PHC-102是有前景的ccRCC SPECT显像示踪剂,可识别不同解剖部位的原发和转移病灶。
  • 该示踪剂可能作为未来CAIX靶向治疗的伴随诊断药物。

研究设计与样本

  • 在5例局限性或转移性透明细胞肾细胞癌患者中开展微剂量研究。
  • 静脉给予总量50 μg CAIX配体、600-800 MBq 99mTc-PHC-102。
  • 于给药后30分钟、2小时、6小时行系列SPECT/CT,分析正常器官与肿瘤的组织分布及滞留时间。

主要发现

  • 5例患者中99mTc-PHC-102耐受良好,未记录研究药物相关不良事件。
  • 胃、肾和胆囊呈快速初始摄取并随时间清除。
  • 5例患者原发肿瘤均见研究药物定位,靶本比良好。
  • 99mTc-PHC-102 SPECT/CT在2例患者中识别出4处既往未知的肺和淋巴结转移。

临床怎么用

  • 99mTc-PHC-102 SPECT/CT可用于ccRCC原发及转移灶的定位评估。
  • 该示踪剂有望作为CAIX靶向治疗的伴随诊断工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

99mTc-PHC-102 is a 99mTc-labeled derivative of acetazolamide, a high-affinity small organic ligand of carbonic anhydrase IX (CAIX). 99mTc-PHC-102 has previously shown favorable in vivo biodistribution properties in mouse models of CAIX-positive clear cell renal cell carcinoma (ccRCC) and colorectal cancer. In this study, we aimed to explore the targeting performance of 99mTc-PHC-102 in SPECT in patients with renal cell carcinoma while also assessing the safety and tolerability of the radiotracer. Methods: We studied 5 patients with localized or metastatic ccRCC in a microdosing regimen, after the administration of a 50-μg total of CAIX ligand and 600-800 MBq of 99mTc-PHC-102. Tissue distribution and residence time in normal organs and tumors were analyzed by serial SPECT/CT scans at 3 time points (30 min, 2 h, and 6 h) after intravenous administration. Results: In the 5 patients studied, 99mTc-PHC-102 was well tolerated and no study drug-related adverse events were recorded. In the stomach, kidneys, and gallbladder, the radiotracer showed a rapid initial uptake, which cleared over time. Localization of the study drug in primary tumors of 5 patients was observed, with favorable tumor-to-background ratios. 99mTc-PHC-102 SPECT/CT allowed the identification of 4 previously unknown lung and lymph node metastases in 2 patients. Conclusion:99mTc-PHC-102 is a promising SPECT tracer for the imaging of patients with ccRCC. This tracer has the potential to identify primary and metastatic lesions in different anatomic locations. 99mTc-PHC-102 might also serve as a companion diagnostic agent for future CAIX-targeting therapeutics.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kulterer OC, Pfaff S, Wadsak W, et al. A Microdosing Study with 99mTc-PHC-102 for the SPECT/CT Imaging of Primary and Metastatic Lesions in Renal Cell Carcinoma Patients. J Nucl Med. 2020. PMID: 32680925. doi:10.2967/jnumed.120.245530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。